Telehealth ADHD Prescribing: What Prescribers Can Do in Texas

If you’re a psychiatrist or psychiatric nurse practitioner considering telehealth ADHD care, you’ve probably asked yourself: Can I legally prescribe Adderall online? What about across state lines? And how do the economics actually work?

The short answer: Yes, psychiatrists can prescribe ADHD medications via telehealth right now—but the rules are more complex than most providers realize, especially if you’re an NP or practicing across multiple states.

Here’s what you actually need to know to build a sustainable telehealth ADHD practice in 2026.

Federal Telehealth Rules: What’s Legal Right Now (and What’s Coming)

The Ryan Haight Act Waiver (Extended Through 2025)

Before COVID-19, the Ryan Haight Act required an in-person medical evaluation before any provider could prescribe Schedule II controlled substances (including Adderall, Ritalin, and Vyvanse) via telemedicine. That changed overnight in March 2020.

The DEA issued emergency waivers allowing psychiatrists to prescribe stimulants through video visits without ever meeting patients face-to-face. That flexibility has now been extended three times—most recently through December 31, 2025 (www.axios.com).

What this means for your practice: As of February 2026, you can still initiate ADHD stimulant prescriptions for new patients entirely via telehealth. You don’t need an in-person visit first.

But there’s a catch.

The 2026 Uncertainty

Unless Congress passes permanent legislation or the DEA creates a new ‘special registration’ pathway for telemedicine prescribing, the default Ryan Haight rules could return. That would require at least one in-person exam before prescribing any Schedule II medication online.

The DEA has proposed a telemedicine special registration system that would allow qualified providers to prescribe controlled substances remotely without the in-person requirement (rxagent.co), but nothing has been finalized yet.

What you should do: Monitor DEA rulemaking through 2026. Have a contingency plan—this might mean partnering with local clinics for in-person evaluations or preparing to transition patients if rules change. For now, you’re fine to continue telehealth ADHD care as usual.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

State-by-State Rules: Where Psychiatrists vs NPs Can Actually Prescribe

Federal law sets the floor, but state law determines who can prescribe what—and that’s where things get complicated, especially for nurse practitioners.

Psychiatrists (MD/DO): Full Authority Everywhere

If you’re a psychiatrist, you have unrestricted prescriptive authority in every state. You can diagnose ADHD via video, prescribe Schedule II stimulants, and manage ongoing medication—subject only to:

• Valid medical license in the patient’s state
• DEA registration for controlled substances
• State-specific telehealth practice standards
• Prescription Drug Monitoring Program (PDMP) checks

No supervision required. No quantity limits (beyond standard 30-day Schedule II rules). You’re practicing at the top of your license.

PMHNPs: It Depends Entirely on Your State

If you’re a psychiatric nurse practitioner, your prescribing authority for ADHD medications varies dramatically by state. Here’s the breakdown for our six priority states:

New York: Full Independence After 3,600 Hours

New York allows PMHNPs to practice fully independently—including prescribing Schedule II stimulants—after completing 3,600 supervised clinical hours (roughly 2 years). Until then, you need a written collaborative agreement with a physician (rxagent.co).

Once you hit that threshold, you can manage ADHD patients just like a psychiatrist: no supervision, no special limits, no physician oversight. New York also mandates PDMP checks before every controlled substance prescription and requires electronic prescribing for all medications.

Bottom line: Experienced NY PMHNPs have essentially the same ADHD prescribing authority as psychiatrists.

Illinois: Full Practice Authority After 4,000 Hours

Illinois operates similarly. PMHNPs can obtain Full Practice Authority after 4,000 clinical hours plus 250 hours of additional post-master’s training (rxagent.co).

Before FPA, you need a Written Collaborative Agreement with a physician who specifically delegates Schedule II prescribing authority. After FPA, you’re independent—no ongoing physician involvement required for routine ADHD prescribing.

Illinois does require physician consultation for Schedule II narcotics (opioids), but that doesn’t apply to stimulants. So once you have FPA, you can prescribe Adderall independently.

Bottom line: Illinois is moving toward NP autonomy—many experienced PMHNPs now practice independently.

California: Transitioning to Independence (But Slowly)

California passed AB 890 in 2020, creating a pathway for NP independence. As of 2023, NPs with at least 3 years (4,600 hours) of experience can apply for ‘Category 104’ independent practice status (rxagent.co).

Until then, you’re a ‘103 NP’ requiring physician supervision in specific healthcare settings. California also requires NPs to complete a specialized pharmacology course before prescribing Schedule II medications (rxagent.co).

The transition is ongoing—by 2026, many experienced California PMHNPs have achieved independence, but newer grads still need physician oversight.

Bottom line: California is phasing in NP autonomy. If you’re newly licensed, plan on 3+ years of collaboration.

Pennsylvania: Restricted with Quantity Limits

Pennsylvania requires all PMHNPs to have a collaborative agreement with a physician—no independent practice option exists yet.

More restrictive: PA law limits NPs to prescribing only a 72-hour supply of Schedule II medications for initial therapy, and 30-day supplies for ongoing treatment (with required physician re-evaluation before continuation) (rxagent.co).

In practice, many PA clinics have the psychiatrist write the initial stimulant prescription to avoid the 72-hour bottleneck, then the NP manages monthly refills under the collaborative agreement.

Bottom line: Pennsylvania NPs need physician partners and face significant prescribing limits for stimulants.

Florida: Supervision Required, But Psychiatric Exception Applies

Florida PMHNPs (‘psychiatric nurses’) must work under a psychiatrist’s protocol—no independent practice for mental health specialties.

Florida law limits APRNs to 7-day supplies of Schedule II drugs, which would make ADHD treatment nearly impossible—except Florida carved out a specific exception: psychiatric medications prescribed by PMHNPs treating mental health conditions are exempt from the 7-day limit (www.leg.state.fl.us).

So you can prescribe a 30-day supply of Adderall—but you must have a written protocol with a supervising psychiatrist.

Florida’s telehealth law explicitly allows prescribing Schedule II medications via telemedicine for psychiatric disorders (www.flsenate.gov), which includes ADHD.

Bottom line: Florida PMHNPs can manage ADHD telehealth effectively, but only with physician collaboration.

Texas: Physicians Only for Stimulants

Texas is the most restrictive state for NP prescribing. All NPs require physician supervision, and Texas law prohibits NPs from prescribing Schedule II controlled substances in outpatient settings—period (rxagent.co).

The only exceptions: hospitalized patients (≥24 hours), emergency departments, or hospice care. Routine outpatient ADHD treatment doesn’t qualify.

Bottom line: In Texas, only psychiatrists (or other MDs) can prescribe stimulant medications for ADHD. NPs can provide therapy and manage non-stimulant ADHD medications (atomoxetine, guanfacine), but not Adderall or Ritalin.

The Clinical Reality: What ADHD Telehealth Actually Looks Like

Initial Evaluation (45-60 Minutes)

ADHD diagnosis is primarily behavioral and historical—which translates well to telehealth:

• Structured clinical interview using DSM-5 criteria
• Rating scales (ADHD RS-IV for children, ASRS for adults) administered electronically
• Collateral information (teacher reports for kids, partner/family input for adults)
• Mental status exam via video observation
• Screening for comorbidities (anxiety, depression, substance use)

You’re not missing much by not having the patient in front of you—ADHD doesn’t require a physical exam. Many psychiatrists ask patients to get baseline vital signs (blood pressure, heart rate) from a primary care visit or home monitor, since stimulants can affect cardiovascular function.

Prescribing and Monitoring

Once you’ve confirmed the diagnosis:

• E-prescribe through a DEA-compliant platform (required in most states)
• Check the state PDMP before prescribing (mandatory in states like New York, Florida, and Texas for controlled substances)
• Start conservative (lower doses, immediate-release formulations) to assess response
• Schedule monthly follow-ups (stimulants are typically dispensed in 30-day supplies without refills due to Schedule II rules)

Monthly visits are usually brief—15 minutes to check symptoms, side effects, adherence, and adjust doses as needed. You’re billing 99213 or 99214 for these.

Compliance and Documentation

Given increased scrutiny of telehealth ADHD prescribing (after some high-profile cases of online ‘pill mills’), best practices include:

• Document thoroughly: Why you diagnosed ADHD, what criteria were met, and why stimulants are medically necessary
• Verify patient identity and location at each visit (for licensure compliance)
• Obtain informed consent covering risks of stimulant therapy
• Set clear expectations with patients about follow-up requirements and refill policies
• Consider urine drug screens if you have concerns about misuse or diversion

This isn’t about being paranoid—it’s about practicing defensibly. Texas legislators specifically called out ‘inappropriate prescribing of Schedule II controlled substances via brief messaging’ as a problem in 2023 (capitol.texas.gov), so demonstrating thorough evaluation and standard-of-care treatment is critical.

Reimbursement: What Telehealth ADHD Care Actually Pays

Here’s the good news: telehealth payment parity is nearly universal for mental health services in 2026 (behavehealth.com).

Almost every state has enacted parity laws or insurer policies requiring equal payment for telehealth visits compared to in-person care. Medicare extended telehealth coverage for mental health through at least 2025, likely permanently (www.kiplinger.com).

What You’ll Actually Get Paid

Medicare rates (2024-2025 fee schedule):

• Initial evaluation (90792): $188-$202 (therathink.com)
• 15-minute medication check (99213): $89-$95 (therathink.com)
• 25-minute medication check (99214): $125-$136 (therathink.com)

Commercial insurance typically pays equal to or 10-30% above Medicare rates—sometimes significantly higher depending on the contract.

Medicaid pays substantially less—roughly $40-$65 for a 15-minute medication management visit (therathink.com)—but many states now cover telepsychiatry at parity.

Real Economics: What Four 15-Minute Visits Per Hour Means

If you’re doing brief medication management visits (which is common for established ADHD patients), you could realistically see:

• 4 patients/hour × $90 (Medicare 99213) = $360/hour gross
• 4 patients/hour × $120 (commercial rate) = $480/hour gross

Compare that to in-person care where you need to factor in:

• Office rent and overhead
• Commute time between locations
• No-show rates (often higher for in-person appointments)
• Administrative time for scheduling and intake

With telehealth, you’re working from home (or wherever), back-to-back video visits, minimal overhead. Even at Medicare rates, the economics work—especially if you’re filling gaps in underserved areas where demand far exceeds supply.

One critical detail: Psychiatrists (MD/DO) are typically reimbursed at higher rates than other mental health providers for medication management services (therathink.com). Your medical license commands premium rates for prescribing work.

The Hidden Challenge: ADHD Medication Shortages

Here’s a pain point every ADHD provider faces right now: stimulant shortages.

Adderall and other ADHD medications have been in intermittent shortage since late 2022 (www.axios.com). Prescriptions surged during the pandemic—between 2020 and 2022, ADHD medication prescribing jumped significantly as more adults sought care via telehealth (apnews.com).

What this means for your practice:

You’ll spend time coordinating with multiple pharmacies to find available stock. You’ll need backup plans—familiarity with alternatives like methylphenidate formulations, non-stimulants (atomoxetine, viloxazine), or even switching between brands when one manufacturer is backordered.

Your patients will be frustrated. You’ll field calls about ‘Why can’t I fill my prescription?’ This isn’t a failure of telehealth—it’s a national supply chain issue—but it’s a workflow reality you need to manage.

Why Psychiatrists Are in High Demand for Telehealth ADHD Care

Let’s talk about the market opportunity:

Massive Provider Shortages in Key States

• Texas: 1 psychiatrist per 9,327 residents (www.healingpsychiatryflorida.com)
• Florida: 1 per 8,577 residents (www.healingpsychiatryflorida.com)
• Pennsylvania: 1 per 4,586 residents (better, but still underserved in rural areas) (www.healingpsychiatryflorida.com)

These ratios are far worse than the national average, and most patients wait months for an appointment with a local psychiatrist.

Rising Adult ADHD Awareness

The pandemic accelerated adult ADHD diagnosis—more people working from home realized they couldn’t focus, more people had time to seek help, and telehealth made it easier to access care (apnews.com).

That demand hasn’t disappeared. Adults who might have never sought ADHD evaluation in a traditional clinic are comfortable with video appointments and online scheduling.

NP Restrictions Create MD Demand

In restricted states like Texas and Pennsylvania, only psychiatrists can independently prescribe stimulants (or NPs with such tight supervision requirements that practices need more MDs anyway).

This makes board-certified psychiatrists especially valuable for telehealth platforms operating across multiple states—you can see patients in any state where you hold a license, without needing collaborative agreements or working around scope-of-practice limits.

How Klarity Health Makes ADHD Telehealth Economically Smart

Here’s where the traditional ‘DIY practice marketing’ math breaks down for most providers:

If you wanted to build your own telehealth ADHD practice from scratch, you’d need:

• SEO investment (6-12 months before meaningful patient flow, $2,000-5,000/month in content, optimization, and technical work)
• Google Ads ($15-40+ per click for mental health keywords; most clicks don’t convert; realistic cost per booked patient: $200-400+)
• Directory listings (Psychology Today, Zocdoc—monthly fees plus per-booking charges, competing with hundreds of other providers)
• Staff time (managing leads, handling no-shows, qualifying patients, follow-up calls)
• Failed campaigns (not every channel works; expect to waste thousands testing)

Total realistic monthly spend: $3,000-5,000 with no guaranteed ROI—and most solo providers don’t have the marketing expertise or patience to make it work.

The Platform Alternative: Pay Only When You See Patients

Klarity Health operates on a pay-per-appointment model. You pay a standard listing fee per new patient lead—no upfront marketing spend, no monthly subscriptions, no wasted ad budget on clicks that don’t convert.

What you get:

• Pre-qualified patients already matched to your specialty and availability (not cold leads you have to screen)
• Built-in telehealth infrastructure (no separate platform costs or technical headaches)
• Both insurance and cash-pay patient flow (depending on your preferences)
• You control your schedule—only pay when patients actually book appointments

The economic reality: Instead of gambling $3,000-5,000/month on marketing that might generate patients, you pay per patient you actually see. That’s guaranteed ROI versus speculative spending.

For ADHD care specifically, where monthly follow-ups are standard, a new patient acquired through Klarity can represent years of ongoing revenue—not just a one-time visit.

State Requirements Summary Table

FAQ: What ADHD Prescribers Actually Want to Know

Can I prescribe ADHD medications to patients in multiple states via telehealth?

Yes—if you hold an active medical license in each state where your patients are located.

You must also have a DEA registration in your primary practice state (and potentially state-controlled substance licenses depending on the state). You cannot prescribe across state lines without being licensed in the patient’s state.

Some states participate in interstate compacts (like the Interstate Medical Licensure Compact for physicians), which can streamline getting multiple licenses.

Do I need to check the prescription monitoring program every time I prescribe?

It depends on your state:

• New York: Yes, mandatory for every controlled substance prescription
• Florida: Yes, for Schedule II-IV
• Texas: Required for opioids/benzos/barbiturates; recommended (but not legally required) for stimulants
• Other states: Check your state board requirements

Even where not strictly required, checking the PDMP is best practice—it protects you from liability and helps identify patients doctor-shopping or at risk of diversion.

What if the federal telehealth allowance expires and in-person visits become required again?

Have a contingency plan:

• Partner with local clinics or primary care offices that can conduct in-person evaluations
• Transition established patients to local providers if they need continued prescriptions
• Focus on non-stimulant ADHD treatments (atomoxetine, viloxazine, guanfacine) that aren’t Schedule II

Most industry observers expect Congress or the DEA to create a permanent pathway rather than reverting to strict in-person requirements—but it’s smart to prepare.

How do I handle medication shortages when patients can’t fill prescriptions?

Build familiarity with alternatives:

• Different stimulant formulations (immediate-release vs extended-release, amphetamine vs methylphenidate)
• Non-stimulant options (atomoxetine, viloxazine, bupropion off-label, clonidine/guanfacine)
• Compound pharmacies (some can prepare stimulant formulations when commercial products are unavailable)

Also maintain relationships with multiple pharmacies in different regions—some may have stock when others don’t. Communicate proactively with patients about potential delays.

Will insurance cover telehealth ADHD visits the same as in-person?

Yes, in almost all cases as of 2026. Payment parity is law or practice in 48+ states (behavehealth.com). Medicare, Medicaid (in most states), and commercial insurers reimburse telehealth medication management at the same rate as office visits.

You may need to use specific billing modifiers (like modifier 95 for telehealth) and document the patient’s location, but reimbursement rates are equivalent.

As a PMHNP, should I try to get licensed in a full-practice-authority state?

If you want true independence, absolutely. States like New York, Illinois, and (increasingly) California allow experienced PMHNPs to practice and prescribe just like psychiatrists—including Schedule II medications.

If you’re currently practicing in a restricted state (Texas, Pennsylvania, Florida), consider obtaining additional licensure in an FPA state to expand your telehealth reach and reduce dependency on physician collaborators.

What’s the biggest compliance risk for telehealth ADHD prescribing?

Inadequate documentation of medical necessity.

State medical boards and the DEA are watching for ‘online pill mills’—providers doing cursory evaluations and reflexively prescribing stimulants. To protect your license:

• Document a thorough diagnostic evaluation meeting DSM-5 criteria
• Record symptom severity, functional impairment, and why medication is appropriate
• Check PDMP and document findings
• Schedule appropriate follow-ups (monthly for new patients on stimulants)
• Be prepared to justify your prescribing patterns if audited

The Bottom Line: Telehealth ADHD Care is Viable—If You Navigate the Rules

Psychiatrists can absolutely build sustainable, well-compensated telehealth practices treating ADHD—but success requires understanding the regulatory landscape, state-by-state scope differences, and real economics of patient acquisition.

Key takeaways:

• Federal rules currently allow telehealth stimulant prescribing (extended through 2025), but uncertainty looms for 2026
• Psychiatrists have full authority everywhere; PMHNPs’ scope varies dramatically by state
• Reimbursement parity is essentially universal—you’ll get paid the same as in-person care
• Demand far exceeds supply in most states, especially Texas, Florida, and rural areas
• DIY marketing is expensive and uncertain; platform models offer guaranteed ROI

If you’re licensed in a shortage state, experienced in ADHD treatment, and comfortable with video care, the opportunity is significant—especially as an MD with unrestricted prescribing authority.

Platforms like Klarity Health remove the marketing risk entirely: instead of spending thousands hoping to attract patients, you pay only when qualified patients actually book appointments. For ADHD care, where monthly follow-ups are standard, each new patient represents ongoing revenue potential—not just a one-time visit.

The regulatory complexity is real, but it’s manageable if you stay informed. And the clinical care? That translates beautifully to telehealth.

Ready to explore telehealth ADHD care without the marketing gamble? Learn how Klarity Health connects psychiatrists and PMHNPs with pre-qualified patients in shortage areas—you control your schedule, we handle patient acquisition.

Sources and Verification

All regulatory and scope-of-practice information in this guide has been verified against current official sources as of February 2026. The following references were used:

Top 5 Primary Citations

1. Florida Statutes §456.47 (Telehealth provisions) – Official state law explicitly allowing Schedule II prescribing via telehealth for psychiatric disorders. www.flsenate.gov (Current through 2023 session)

2. Axios News – ‘COVID-era telehealth prescribing extended again’ – Confirms DEA extension of controlled substance prescribing flexibility through December 31, 2025. www.axios.com (Published November 18, 2024)

3. RxAgent ‘NP Prescriptive Authority by State (2026 Guide)’ – Comprehensive state-by-state breakdown of nurse practitioner scope and Schedule II prescribing limits. rxagent.co (Updated December 28, 2025)

4. Therathink – ‘Insurance Reimbursement Rates for Psychiatrists [2026]’ – Detailed Medicare and commercial insurance reimbursement data for psychiatric CPT codes. therathink.com (Updated 2026)

5. Healing Psychiatry Florida – ‘Psychiatrist Shortage by State’ – State-by-state workforce data showing psychiatrist-to-population ratios and shortage areas. www.healingpsychiatryflorida.com (Published January 15, 2026)

Additional References

Federal and State Regulations:

• Texas Capitol – SB 2527 Bill Analysis (88th Legislature) on telehealth prescribing standards. capitol.texas.gov (April 2023)
• Florida Statutes §464.012 – APRN prescribing authority and psychiatric nurse exception to 7-day Schedule II limit. www.leg.state.fl.us
• Center for Connected Health Policy (CCHP) – Texas state telehealth laws summary. www.cchpca.org (Updated January 19, 2026)

Healthcare Trends and Policy:

• Associated Press – ‘More adults sought help for ADHD during pandemic’ (ADHD prescription surge data). apnews.com (January 10, 2024)
• Axios – ‘Telehealth prescribing mess could reach Congress’ (federal policy outlook). www.axios.com (September 18, 2024)
• BehaveHealth – ‘Mental Health Reimbursement Trends’ (telehealth parity status). behavehealth.com (2024)
• Kiplinger – ‘Medicare telehealth expanded in 2025’ (Medicare telehealth coverage). www.kiplinger.com

All information reflects regulatory status as of late February 2026. Federal telehealth prescribing rules remain subject to change pending DEA rulemaking and potential Congressional action through 2026. State laws cited are current as of latest legislative sessions (2023-2025).

Reliability note: Official statutes and government documents = High reliability (authoritative legal sources). Industry analyses and healthcare news = Medium-High reliability (credible secondary sources, cross-verified with official data). No pre-2024 sources were used for dynamic regulatory information.

Source:

• https://www.axios.com/2024/09/18/telehealth-services-controlled-substances-congress#:~:text=Why%20it%20matters%3A%20Pandemic,end%20of%20this%20year%20after
• https://www.axios.com/2024/11/18/covid-telehealth-prescribing-extended-adderall#:~:text=The%20Drug%20Enforcement%20Administration%20and,the%20third%20temporary%20extension%20of
• https://www.flsenate.gov/Laws/Statutes/2023/456.47#:~:text=,is%20prescribed%20for%20the%20following
• https://www.flsenate.gov/Laws/Statutes/2023/456.47#:~:text=1,disorder
• https://rxagent.co/blog/np-prescribing-authority#:~:text=OK%20%20,day%20%28ongoing%29%20%5B3
• https://rxagent.co/blog/np-prescribing-authority#:~:text=TN%20%20,NP%3A%20Independent%20%5B3
• https://rxagent.co/blog/np-prescribing-authority#:~:text=match%20at%20L210%20NY%20,terminal%20illness%2C%20MD%20initiation
• https://rxagent.co/blog/np-prescribing-authority#:~:text=ID%20%20,3
• https://rxagent.co/blog/np-prescribing-authority#:~:text=FL%20%20,NP%3A%20Independent%20%5B3
• https://www.leg.state.fl.us/STATUTeS/index.cfm?Appmode=DisplayStatute&Search_String=&URL=0400-0499%2F0464%2FSections%2F0464.012.html#:~:text=also%20limit%20the%20prescribing%20of,shall%20adopt%20by%20rule%20the